Loading…
Geron Corporation is projected to rise to $1.55 by 2027, a +3% move from its current price of $1.50. GERN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.46 | $1.50 | $1.54 | -0.02% |
| Jul 14 | $1.44 | $1.50 | $1.56 | -0.04% |
| Jul 15 | $1.42 | $1.50 | $1.58 | -0.05% |
| Jul 16 | $1.41 | $1.50 | $1.59 | -0.07% |
| Jul 17 | $1.40 | $1.50 | $1.60 | -0.09% |
| Jul 18 | $1.39 | $1.50 | $1.61 | -0.11% |
| Jul 19 | $1.39 | $1.50 | $1.62 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.39 | $1.50 | $1.62 | -0.13% |
| Week 2 | $1.34 | $1.50 | $1.67 | -0.25% |
| Week 3 | $1.31 | $1.49 | $1.71 | -0.38% |
| Week 4 | $1.28 | $1.49 | $1.74 | -0.51% |
| Week 5 | $1.25 | $1.49 | $1.77 | -0.64% |
| Week 6 | $1.23 | $1.49 | $1.80 | -0.76% |
| Week 7 | $1.21 | $1.49 | $1.83 | -0.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Geron Corporation is a commercial-stage biopharmaceutical company focusing on oncology. Its product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 for lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 for higher risk myelodysplastic syndromes and acute myeloid leukemia; IMproveMF which is in Phase 1 for frontline myelofibrosis; and IMAGINE which is in Phase 1/2 for relapsed/refractory AML. Geron was incorporated in 1990 and is headquartered in Foster City, California.
Geron trades at $1.49 with a market cap of $955.87M, ranking 2605. The current price sits within a framework of ongoing development across its oncology-focused pipeline and a long-run forecast that supports upside potential.
A major floor 38.2% below — a decisive break under it would weaken the trend.
The nearest floor, 26.7% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 23.1% above — clearing it would confirm fresh momentum.
Key GERN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GERN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.51 | Sell | $1.49 | Buy |
| MA 10 | $1.41 | Buy | $1.44 | Buy |
| MA 20 | $1.33 | Buy | $1.37 | Buy |
| MA 50 | $1.33 | Buy | $1.36 | Buy |
| MA 100 | $1.48 | Buy | $1.40 | Buy |
| MA 200 | $1.39 | Buy | $1.48 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.13 | Neutral |
| Stoch RSI (14) | 66.33 | Neutral |
| CCI (20) | 107.69 | Buy |
| Williams %R (14) | -20.69 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 11.11 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 79.31 | Neutral |
| TRIX (15) | 0.33 | Buy |
| Awesome (5,34) | 0.23 | Buy |
| Ultimate (7,14,28) | 74.94 | Sell |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1.60 | Sell |
| ADX (14) | 25.10 | Buy |
| ATR (14) | 0.04 | Info |
Sentiment is BULLISH with RSI14 at 70. The 50-day simple moving average stands at $1.33 and the 200-day simple moving average at $1.39, with a defined support at $1.10 and a resistance at $1.49. The 30-day range spans from $1.23 to $1.81, outlining a tight near-term trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.10 | $1.50 | $1.91 | 0% | Neutral | |
| $1.22 | $1.55 | $2.08 | +3% | Neutral | |
| $1.33 | $1.74 | $2.42 | +16% | Neutral | |
| $1.29 | $1.72 | $2.47 | +15% | Neutral | |
| $1.50 | $2.05 | $3.03 | +37% | Bullish | |
| $1.84 | $2.57 | $3.87 | +71% | Bullish | |
| $1.78 | $2.53 | $3.89 | +69% | Bullish | |
| $1.81 | $2.62 | $4.10 | +74% | Bullish | |
| $1.85 | $2.72 | $4.34 | +82% | Bullish | |
| $1.79 | $2.67 | $4.32 | +78% | Bullish | |
| $2.60 | $4.19 | $7.24 | +179% | Bullish | |
| $4.54 | $8.31 | $15.77 | +454% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.10 | $1.50 | $1.83 | +0.00% |
| August 2026 | $1.27 | $1.50 | $1.83 | +0.20% |
| September 2026 | $1.24 | $1.48 | $1.82 | -1.84% |
| October 2026 | $1.26 | $1.51 | $1.88 | +2.68% |
| November 2026 | $1.28 | $1.54 | $1.93 | +1.58% |
| December 2026 | $1.25 | $1.51 | $1.91 | -1.55% |
Click any year to see its month-by-month GERN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GERN is projected to trade between $1.10 and $1.91, averaging $1.50 — a potential gain of 0% from today's $1.50. A consolidation phase looks the most probable path here.
Geron Corporation's 2027 outlook centres on $1.55, within a $1.22 to $2.08 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2028, GERN could reach as high as $2.42, with a base case around $1.74 and support toward $1.33 — roughly +16% from $1.50. A consolidation phase looks the most probable path here.
Expect GERN to range from $1.29 to $2.47 through 2029. The $1.72 average target implies a +15% move from current prices. That is -1% versus the projected 2028 average. Price action looks broadly range-bound.
The GERN price prediction for 2030 points to an average of $2.05 (low $1.50, high $3.03) — a potential gain of +37% on today's $1.50. Buyers look set to stay in control over this stretch.
In 2031, GERN is projected to trade between $1.84 and $3.87, averaging $2.57 — a potential gain of +71% from today's $1.50. That is up +25% on the projected 2030 average. Momentum favours further upside here.
Geron Corporation's 2032 outlook centres on $2.53, within a $1.78 to $3.89 range. That is -2% versus the projected 2031 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, GERN could reach as high as $4.10, with a base case around $2.62 and support toward $1.81 — roughly +74% from $1.50. Momentum favours further upside here.
Expect GERN to range from $1.85 to $4.34 through 2034. The $2.72 average target implies a +82% move from current prices. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The GERN price prediction for 2035 points to an average of $2.67 (low $1.79, high $4.32) — a potential gain of +78% on today's $1.50. Momentum favours further upside here.
In 2040, GERN is projected to trade between $2.60 and $7.24, averaging $4.19 — a potential gain of +179% from today's $1.50. That is up +57% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Geron Corporation's 2050 outlook centres on $8.31, within a $4.54 to $15.77 range. That is up +98% on the projected 2040 average. That marks a +454% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GERN today (≈ 666.666667 GERN) could be worth
$5,537.83
+$4,537.83 (+454%) by 2050 · US Dollar
Based on the average projected GERN price of $8.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GERNwould be worth at today's price.
$1,000 invested in GERN on Jul 10, 2025 (≈ 724.637684 GERN) would be worth
$1,086.96
+$86.96 (+8.7%) today · 1.09× · US Dollar
Based on a GERN entry price of $1.38 vs. today's $1.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.36 | $1,102.94 | +10.3% |
| 1 month ago | $1.1 | $1,363.64 | +36.4% |
| 3 months ago | $1.67 | $898.2 | -10.2% |
| 6 months ago | $1.43 | $1,048.95 | +4.9% |
| 1 year ago | $1.38 | $1,086.96 | +8.7% |
| All time (5.0y) ago | $1.27 | $1,181.1 | +18.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GERN forecast.
Our base-case forecast reaches $3.00 around 2040.
Implied market cap at $3.00: $1.92B
The multi-year forecast shows a bullish trajectory beginning in 2030, with the average price rising to $1.95 and a max of $2.88 in 2030, and continuing to milestones such as $3.84 average by 2040 and $7.46 average by 2050. The 2030, 2040 and 2050 forecasts carry average prices of $1.95, $3.84 and $7.46 with max prices of $2.88, $6.64 and $14.17 respectively. ROI figures strengthen over time, at 30.9% in 2030, 157.5% in 2040, and 400.6% in 2050, with bullish sentiment persisting in those years.
Near-term forecasts through 2029 show NEUTRAL sentiment, transitioning to BULLISH in the 2030s and beyond, consistent with the long-run path of rising averages and upside potential while noting these are estimates rather than guarantees.
Tap a question to reveal the answer.
Avg $1.95, min $1.43, max $2.88; ROI 30.9%; sentiment BULLISH.
Near-term forecasts (through 2029) show NEUTRAL sentiment with gradual upside over time; by 2030 the avg price is $1.95 and by 2050 the avg is $7.46, with ROI reaching 400.6%. These are estimates, not guarantees.
Yes. The 2040 max forecast is $6.64, indicating a potential to reach that level in the 2040 horizon (2030 max $2.88; 2040 max $6.64; 2050 max $14.17).
The current price is $1.49 and the market cap is $955.87M.
Avg $7.46, min $4.07, max $14.17; ROI 400.6%; sentiment BULLISH.
Geron Corporation Community Discussion
0Share your Geron Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.